PTI-1

PTI-1 (SGT-48) is an indole-based synthetic cannabinoid.^[1] It is one of few synthetic cannabinoids containing a thiazole group and is closely related to PTI-2. These compounds may be viewed as simplified analogues of indole-3-heterocycle compounds originally developed by Organon and subsequently further researched by Merck.^[2][3][4]

PTI-1

Legal status
Legal status	CA: Schedule II DE: NpSG (Industrial and scientific use only) UK: Class B
Identifiers
IUPAC name N,N-diethyl-N-((2-(1-pentyl-1H-indol-3-yl)thiazol-4-yl)methyl)ethanamine
CAS Number	1400742-46-2
PubChem CID	124037378
ChemSpider	32055537
UNII	FSE9R26430
Chemical and physical data
Formula	C21H29N3S
Molar mass	355.54 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCCN1C=C(C2=NC(CN(CC)CC)=CS2)C3=CC=CC=C31.Cl
InChI InChI=1S/C21H29N3S.ClH/c1-4-7-10-13-24-15-19(18-11-8-9-12-20(18)24)21-22-17(16-25-21)14-23(5-2)6-3;/h8-9,11-12,15-16H,4-7,10,13-14H2,1-3H3;1H Key:NPYOTZAJIONLKZ-UHFFFAOYSA-N

See also

• JWH-018
• LBP-1 (drug)
• PTI-2